Skip to main content
. Author manuscript; available in PMC: 2021 Sep 1.
Published in final edited form as: Ophthalmology. 2020 Mar 29;127(9):1201–1210. doi: 10.1016/j.ophtha.2020.03.021

Figure 2.

Figure 2.

Distribution of the number of anti-vascular endothelial growth factor (VEGF) injections received between 3 to 5 years after initial randomization into a 2-year clinical trial on anti-VEGF treatment for diabetic macular edema (Protocol T).